Background
The World Health Organization (WHO) recommends twice-yearly lenacapavir as long-acting pre-exposure prophylaxis (PrEP), offering an alternative to oral PrEP. WHO advises using rapid and self-administered HIV tests with long-acting PrEP and emphasizes flexible testing to avoid limiting access. Rapid tests have reduced sensitivity, particularly during the acute stage of infection. Starting lenacapavir during undiagnosed infection may lead to ongoing transmission and emergence of drug resistance, potentially reducing its population-level effectiveness. This study evaluates how HIV testing strategies influence lenacapavir’s preventive impact and resistance transmission in Thailand, where its rollout is being planned.
Methods
We developed a mathematical HIV transmission model among men who have sex with men (MSM) in Thailand, including oral and long-acting PrEP. The model was calibrated using data on MSM population size, HIV prevalence, annual new diagnoses, and CD4 count at diagnosis. We projected PrEP use to increase from 50,000–80,000 to 100,000 over the next decade, with 20%-100% using lenacapavir for two years. Resistance was assumed to emerge in 50%-100% of individuals starting lenacapavir during unrecognized HIV infection, with resistant strains having 30%-50% lower transmissibility. Over a 20-year horizon, we evaluated outcomes using a perfectly accurate HIV test as the reference scenario. We assessed the epidemiological impact and resistance transmission under scenario’s where rapid and self-tests fail to detect acute HIV infections, and where individuals are tested only once annually.
Results
Without lenacapavir, 57,000 new HIV infections are projected over 20 years. Lenacapavir could prevent 5,500-17,800 infections (with 20%-100% lenacapavir uptake). Rapid testing reduces infections averted by about 4%, regardless of uptake or testing frequency. Lenacapavir may result in 12–24 drug-resistant infections (0.02% of all new infections). Compared to perfect tests, under a scenario of rapid testing, resistance could increase by 6-12 individuals (50% relative rise) or double to 24-47 individuals if rapid testing is performed only annually.
Conclusions
Rapid HIV testing and less frequent testing are associated with a modest increase in new infections and drug-resistant HIV transmission. However, absolute numbers remain low. These findings support the use of rapid tests, including self-testing to expand access to lenacapavir as a long-acting PrEP option.